Celyad SA (CYAD): Price and Financial Metrics


Celyad SA (CYAD)

Today's Latest Price: $10.27 USD

0.12 (1.18%)

Updated Aug 7 3:49pm

Add CYAD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

CYAD Stock Summary

  • With a price/sales ratio of 21,142.51, Celyad Oncology SA has a higher such ratio than 99.93% of stocks in our set.
  • With a year-over-year growth in debt of 529.59%, Celyad Oncology SA's debt growth rate surpasses 96.68% of about US stocks.
  • Revenue growth over the past 12 months for Celyad Oncology SA comes in at 94.83%, a number that bests 94.06% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CYAD, based on their financial statements, market capitalization, and price volatility, are NK, ADVM, TGTX, URGN, and WKHS.
  • CYAD's SEC filings can be seen here. And to visit Celyad Oncology SA's official web site, go to www.celyad.com.
CYAD Daily Price Range
CYAD 52-Week Price Range

CYAD Stock Price Chart Technical Analysis Charts


CYAD Price/Volume Stats

Current price $10.27 52-week high $14.98
Prev. close $10.15 52-week low $4.10
Day low $10.23 Volume 1,016
Day high $10.30 Avg. volume 19,607
50-day MA $10.84 Dividend yield N/A
200-day MA $9.85 Market Cap 143.18M

Celyad SA (CYAD) Company Bio


Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.





CYAD Latest News Stream


Event/Time News Detail
Loading, please wait...

CYAD Latest Social Stream


Loading social stream, please wait...

View Full CYAD Social Stream

Latest CYAD News From Around the Web

Below are the latest news stories about Celyad Oncology SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.

Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate

Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.

Yahoo | July 15, 2020

Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Regulatory News:

Yahoo | July 14, 2020

Celyad to add "Oncology" to corporate name

Calling it a "rebranding,", Celyad (CYAD) will now do business as Celyad Oncology. The ticker will remain as is....

Seeking Alpha | June 10, 2020

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

Yahoo | May 27, 2020

All You Need to Know About Celyad SA (CYAD) Rating Upgrade to Strong Buy

Celyad SA (CYAD) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | May 25, 2020

Read More 'CYAD' Stories Here

CYAD Price Returns

1-mo 0.20%
3-mo 9.02%
6-mo -2.28%
1-year -22.31%
3-year -76.55%
5-year -81.48%
YTD -1.44%
2019 -42.62%
2018 -57.87%
2017 142.68%
2016 -67.47%
2015 N/A

Continue Researching CYAD

Want to see what other sources are saying about Celyad Sa's financials and stock price? Try the links below:

Celyad Sa (CYAD) Stock Price | Nasdaq
Celyad Sa (CYAD) Stock Quote, History and News - Yahoo Finance
Celyad Sa (CYAD) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0275 seconds.